Logo

News

Call for participants (5-11 years old): Immunotherapy study for peanut allergy

A study to look at a new investigational immunotherapy for peanut allergy is presently underway at Inflamax Research in Mississauga, Ontario.

The research team is seeking children aged 5-11 years with a peanut allergy, with no history of anaphylaxis, to participate in this study.

Please see their call for participants below for more details. If your child is interested in participating, we encourage you to contact the research team directly to learn more about potential risks and benefits of this study, and to also speak with your child’s physician.

Please also share with other families who may be interested in this study.


From the research team

Currently, there is no effective treatment for peanut allergy other than avoidance of peanut allergens. Our experienced research team, led by Dr. Peter Couroux, is working closely with pharmaceutical organizations to explore therapies for people with peanut allergy. Currently we are conducting a peanut allergy study for children. The details are summarized below:

We are currently enrolling children 5 to 11 years of age in a study examining the safety and tolerability of an immunotherapy injection just under the skin with an investigational modified peanut extract. If you are a parent of a child with a peanut allergy, we invite you to contact us.

Eligibility

  • Participants: Must be between 5 to 11 years of age; both parents/guardian(s) must sign a consent form before screening procedures.
  • Diagnosis: Your child must have received a peanut allergy diagnosis from an allergist, family doctor, or pediatrician. Participants should not have a history of severe anaphylaxis.
  • Other: Your child must be able to travel to our Mississauga clinic for weekly visits.

How to participate

  • Step 1: Pass a telephone questionnaire; approximately a 20 minute call with a recruitment coordinator.
  • Step 2: Attend a screening visit at the Inflamax Research clinic in Mississauga, Ontario.
  • Step 3: Once your child is deemed eligible for the study, there will be 18-23 scheduled weekly visits in total to the Inflamax Research clinic to complete the immunotherapy dosing schedule (each visit would last approximately 5 hours). The clinic visits should take around 4 months to complete.
  • Step 4: Participate in 3 follow-up phone calls upon completing the dosing schedule.

Compensation for participation

  • Participants who successfully complete the study will be compensated up to $4,500 (depending on number of visits completed).

Confidentiality

Participation in these studies is entirely voluntary. You may refuse to participate or you may discontinue your participation at any time without explanation. All information obtained during these studies will be kept strictly confidential to the extent allowable by law. The research data will be available only to the research team. This study has been reviewed by IRB Services, an independent Research Ethics Board.

Registration

Click on this link to register: http://www.sneezetoronto.com/peanut-allergy-study-for-children/ or call into the recruitment centre at 905-282-1808. Registration will be open until September 21, 2018.

Questions

If you have any questions, please contact Jodi Graham, Recruitment Coordinator, at jgraham@inflamaxresearch.com or call 905-282-1808.

More information on the study can be found on the ClinicalTrials.gov site: https://clinicaltrials.gov/ct2/show/NCT02991885?term=couroux&cond=Peanut+Allergy&rank=1